Ticker: WX, Company: WuXi PharmaTech (Cayman) Inc., Type: 20-F, Date: 2009-06-25
Original SEC Filing: Click here

---

Webplus: WX/20090625/20-F/1/000.htm SEC Original: d20f.htm
TABLE OF CONTENTS Page INTRODUCTION 1 2 PART I. ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THE COMPANY 28 ITEM 4A. UNRESOLVED STAFF COMMENTS 47 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 47 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND

---

---

Webplus: WX/20090625/20-F/2_EX-1.1/000.htm SEC Original: dex11.htm
SECOND AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF WUXI PHARMATECH (CAYMAN) INC. Adopted by Special Resolution passed on July 27, 2007 and effective immediately upon completion of the Company’s initial public offering of ordinary shares represented by American Depositary Shares Note: This document additionally reflects the amendment made to Article 80(1) on September 10, 2008 WuXi PharmaTech (Cayman) Inc. 1.

---

---

Webplus: WX/20090625/20-F/3_EX-4.3/000.htm SEC Original: dex43.htm
EXECUTION VERSION ACT WUXI PHARMATECH (BVI) INC. CONVERTIBLE NOTE US$[Amount] 1 February [Date], 2007 Company Holder Principal Amount Maturity Date WUXI PHARMATECH (BVI) INC., a company incorporated and existing under the laws of the British Virgin Islands (the “ The following is a statement of the rights of the Holder of this Note and the conditions to which this Note

---

---

Webplus: WX/20090625/20-F/4_EX-4.14/000.htm SEC Original: dex414.htm
SECOND AMENDMENT TO OFFICE AND INDUSTRIAL LEASE AGREEMENT LIBERTY PROPERTY PHILADELPHIA LIMITED PARTNERSHIP V Landlord WUXI APPTEC INC., Tenant APPTEC LABORATORY SERVICES, LLC, Assignor THIS AMENDMENT is entered into on December 30, 2008, by and between WHEREAS, WHEREAS NOW, THEREFORE, 1. All capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings given to them

---

---

Webplus: WX/20090625/20-F/5_EX-4.16/000.htm SEC Original: dex416.htm
SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this “Amendment”) is made as of April 30, 2008 (the “Amendment Date”) by and between ALPHA EXCHANGE, LLC, a Georgia limited liability company (successor-in-interest to Highwoods Realty Limited Partnership) (“Landlord”) and WUXI APPTEC, INC., a Delaware corporation (f/k/a Apptec Laboratory Services, Inc., a Delaware corporation) (“Tenant”). RECITALS Landlord and Tenant hereby

---

---

Webplus: WX/20090625/20-F/6_EX-4.18/000.htm SEC Original: dex418.htm
FIRST AMENDMENT TO LEASE Amendment , Landlord Tenant This First Amendment to Lease (this Recitals: A. Original Lease Original Premises B. Expansion Premises Expansion Date C. D. NOW, THEREFORE, Landlord and Tenant agree as follows: 1. Interpretation “Lease” 2. Expansion of Premises 1 First Amendment to Lease AppTec Laboratory Services, Inc. 3. Extension of Initial Term 4. Net Rent Period

---

---

Webplus: WX/20090625/20-F/7_EX-8.1/000.htm SEC Original: dex81.htm
LIST OF SUBSIDIARIES • • WX (BVI) Limited, incorporated in the British Virgin Islands. • WuXi AppTec (BVI) Inc., incorporated in the British Virgin Islands. • • Kaipara Enterprises Limited, incorporated in Cyprus. • Klivia Investments Sp. zo.o., incorporated in Poland. • Klivia Investments Sp. zo.o. Luxembourg Branch, incorporated in Luxembourg. • WuXi AppTec Co., Ltd., incorporated in the People’s

---

---

Webplus: WX/20090625/20-F/8_EX-12.1/000.htm SEC Original: dex121.htm
Certification by the Chief Executive Officer I, Ge Li, Chief Executive Officer of WuXi PharmaTech (Cayman) Inc. (the “Company”), certify that: 1. I have reviewed this annual report on Form 20-F of the Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to

---

---

Webplus: WX/20090625/20-F/9_EX-12.2/000.htm SEC Original: dex122.htm
Certification by the Acting Chief Financial Officer I, Edward Hu, Acting Chief Financial Officer of WuXi PharmaTech (Cayman) Inc. (the “Company”), certify that: 1. I have reviewed this annual report on Form 20-F of the Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact

---

---

Webplus: WX/20090625/20-F/10_EX-13.1/000.htm SEC Original: dex131.htm
Section 906 of the Sarbanes-Oxley Act of 2002 Ge Li Chief Executive Officer

---

---

Webplus: WX/20090625/20-F/11_EX-13.2/000.htm SEC Original: dex132.htm
Section 906 of the Sarbanes-Oxley Act of 2002 Edward Hu Acting Chief Financial Officer

---

---

Webplus: WX/20090625/20-F/12_EX-23.1/000.htm SEC Original: dex231.htm
Commerce & Finance Law Offices 6F NCI Tower, A12 Jianguomenwai Avenue, Chaoyang District, Beijing, PRC; Postcode: 100022 Tel:(8610) 65693399 Fax: (8610) 65693838,65693836, 65693837, 65693839 www.tongshang.com.cn E-mail Add: beijing@tongshang.com Website: June 25, 2009 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China RE: WUXI PHARMATECH (CAYMAN) INC. Dear Sirs/Madams, Company We have

---

---

Webplus: WX/20090625/20-F/13_EX-23.2/000.htm SEC Original: dex232.htm
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-146730 on Form S-8 of our reports dated June 25, 2009, relating to the financial statements and financial statement schedule of WuXi PharmaTech (Cayman) Inc., and the effectiveness of WuXi PharmaTech (Cayman) Inc.’s internal control over financial reporting, appearing in this Annual

---

Company Information:

Ticker: WX, Company: WuXi PharmaTech (Cayman) Inc., Type: 20-F, Date: 2009-06-25CIK: 0001403132, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
288 FUTE ZHONG ROAD
SHANGHAI 200131